186 related articles for article (PubMed ID: 34739582)
21. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
22. Lurbinectedin-induced thrombocytopenia: the role of body surface area.
Papachristos A; Ratain MJ
Cancer Chemother Pharmacol; 2022 May; 89(5):573-575. PubMed ID: 35362793
[TBL] [Abstract][Full Text] [Related]
23. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
25. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Kristeleit R; Leary A; Delord JP; Moreno V; Oaknin A; Castellano D; Shappiro GI; Fernández C; Kahatt C; Alfaro V; Siguero M; Rueda D; Zeaiter A; Awada A; Santaballa A; Zaman K; Sehouli J; Subbiah V
Invest New Drugs; 2023 Oct; 41(5):677-687. PubMed ID: 37556023
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Jimeno A; Sharma MR; Szyldergemajn S; Gore L; Geary D; Diamond JR; Fernandez Teruel C; Soto Matos-Pita A; Iglesias JL; Cullell-Young M; Ratain MJ
Invest New Drugs; 2017 Aug; 35(4):471-477. PubMed ID: 28105566
[TBL] [Abstract][Full Text] [Related]
27. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
[TBL] [Abstract][Full Text] [Related]
28. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
[TBL] [Abstract][Full Text] [Related]
29. Lurbinectedin: First Approval.
Markham A
Drugs; 2020 Sep; 80(13):1345-1353. PubMed ID: 32816202
[TBL] [Abstract][Full Text] [Related]
30. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
Elez ME; Tabernero J; Geary D; Macarulla T; Kang SP; Kahatt C; Pita AS; Teruel CF; Siguero M; Cullell-Young M; Szyldergemajn S; Ratain MJ
Clin Cancer Res; 2014 Apr; 20(8):2205-14. PubMed ID: 24563480
[TBL] [Abstract][Full Text] [Related]
31. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
[No Abstract] [Full Text] [Related]
32. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
33. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
Singh S; Jaigirdar AA; Mulkey F; Cheng J; Hamed SS; Li Y; Liu J; Zhao H; Goheer A; Helms WS; Wang X; Agarwal R; Pragani R; Korsah K; Tang S; Leighton J; Rahman A; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 May; 27(9):2378-2382. PubMed ID: 33288660
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
35. De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.
Chakraborty S; Coleman C; Manoj P; Demircioglu D; Shah N; de Stanchina E; Rudin CM; Hasson D; Sen T
Clin Cancer Res; 2023 Sep; 29(17):3526-3540. PubMed ID: 37382635
[TBL] [Abstract][Full Text] [Related]
36. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
37. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
[TBL] [Abstract][Full Text] [Related]
38. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
39. Lurbinectedin (Zepzelca) for small-cell lung cancer.
Med Lett Drugs Ther; 2022 Nov; 64(1663):e198-e199. PubMed ID: 36384771
[No Abstract] [Full Text] [Related]
40. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P; Altares R; van Andel L; Lubomirov R; Fudio S; Rosing H; Márquez Del Pino FM; Tibben MM; Benedit G; Nan-Offeringa L; Luepke Estefan XE; Francesch A; Zeaiter A; Cuevas C; Schellens JHM; Beijnen JH
Drug Metab Dispos; 2022 Apr; 50(4):327-340. PubMed ID: 35042701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
